EPISODE · Jul 14, 2022 · 9 MIN
FDA reviews first-ever OTC birth control application
from POLITICO's Pulse Check · host POLITICO
The Food and Drug Administration is reviewing a first-of-its-kind application from HRA Pharma for Opill. If green-lit by the agency, Opill would become the first daily, hormonal birth control pill sold without a prescription. The submission of the application follows more than six years of studies the company has run. Alice Miranda Ollstein reports. Learn more about your ad choices. Visit megaphone.fm/adchoices
What this episode covers
The Food and Drug Administration is reviewing a first-of-its-kind application from HRA Pharma for Opill. If green-lit by the agency, Opill would become the first daily, hormonal birth control pill sold without a prescription. The submission of the application follows more than six years of studies the company has run. Alice Miranda Ollstein reports. Learn more about your ad choices. Visit megaphone.fm/adchoices
NOW PLAYING
FDA reviews first-ever OTC birth control application
No transcript for this episode yet
Similar Episodes
Jun 20, 2026 ·2m
Jun 20, 2026 ·2m
Jun 15, 2026 ·3m
Jun 15, 2026 ·3m
Jun 14, 2026 ·2m
Jun 14, 2026 ·2m